GlassScriptPhysician profile
Mazan Rabadi
NPI 1235174194
$4,864.97
in general payments reported to CMS, 2019-2025
33 companies · $1,686 in 2025
The $1,686 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $305 · 2020: $49.25 · 2021: $144 · 2022: $144 · 2023: $996 · 2024: $1,542 · 2025: $1,686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,223.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,223.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $488.38 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $383.66 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $315.58 | 2023-2025 | Caplyta |
| Exact Sciences Corporation | $313.27 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $300.48 | 2023-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $298.51 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $268.65 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $266.44 | 2025 | Recorlev |
| Pfizer INC. | $262.70 | 2019-2025 | |
| Amgen INC. | $227.57 | 2024-2025 | Otezla, Repatha, Evenity |
| Lundbeck LLC | $216.42 | 2023-2024 | Rexulti |
| Abbott Laboratories | $212.71 | 2023-2025 | Freestyle Libre, Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $191.38 | 2023-2025 | Rexulti |
| Lilly USA, LLC | $190.25 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Celgene Corporation | $139.98 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $103.50 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.45 | 2023-2025 | Jardiance, Tradjenta |
| Idorsia Pharmaceuticals US INC | $66.56 | 2023 | Quviviq |
| Corcept Therapeutics | $65.59 | 2024 | Korlym |
| E.R. Squibb & Sons, L.L.C. | $61.48 | 2020-2024 | Camzyos |
| Teva Pharmaceuticals USA, INC. | $55.56 | 2025 | Austedo Xr |
| Electromed, INC. | $50.82 | 2024-2025 | Smartvest |
| Allergan, INC. | $42.86 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.80 | 2025 | |
| Scpharmaceuticals INC. | $34.66 | 2025 | |
| Janssen Pharmaceuticals, INC | $30.41 | 2024 | Spravato |
| Almatica Pharma LLC | $28.24 | 2023 | Gralise, Loreev Xr |
| Shield Therapeutics INC | $22.60 | 2024 | |
| Collegium Pharmaceutical, INC. | $22.42 | 2024 | Xtampza |
| Sumitomo Pharma America, INC. | $20.58 | 2025 | Gemtesa |
| Medtronic, INC. | $19.40 | 2023 | Closurefast |
| Currax Pharmaceuticals LLC | $16.84 | 2025 | Contrave |
| Linus Health, INC. | $14.22 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mazan Rabadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.